On December 19th, Bristol Myers Squibb announced that the company has reached an agreement with AbbVie Pharmaceuticals to regain exclusive rights to develop and commercialize ABZ-706 (equivalent to RYZ801) in the Greater China market for RayzeBio pipeline products. This pipeline product is used for liver cancer treatment targeting GPC3 targets, and a broad licensing agreement previously signed with AbbVie has been terminated, granting AbbVie the right to develop and commercialize up to four RayzeBio pipeline products (including ABZ-706) in these markets.